Unilateral Multifocality Is Not a Risk Factor for Recurrence After Thyroid Lobectomy: A Study of 1,684 Patients With Differentiated Thyroid Cancer

被引:1
|
作者
Cho, Jin-Seong [1 ]
Kim, Hee Kyung [2 ]
机构
[1] Chonnam Natl Univ, Dept Surg, Med Sch, Gwangju, South Korea
[2] Chonnam Natl Univ, Dept Internal Med, Med Sch, 42 Jebong ro, Gwangju 61469, South Korea
来源
IN VIVO | 2023年 / 37卷 / 04期
关键词
Multifocality; differentiated thyroid cancer; lobectomy; risk factors; recurrence; PROGNOSTIC-FACTOR; TUMOR; CARCINOMA; NUMBER;
D O I
10.21873/invivo.13270
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background/Aim: Many studies indicate that multifocality is associated with high-risk features of differentiated thyroid cancer (DTC). Herein, we evaluated the impact of the unilateral multifocality on post-lobectomy recurrence in patients with DTC. Patients and Methods: We retrospectively analyzed 1,684 patients with DTC who underwent thyroid lobectomy from 2008 to 2015 using logistic regression models to calculate the relative risk on post-lobectomy recurrence. Results: Tumor diameter increased from 4.9 mm to 8.1 mm and the proportion of extrathyroidal extension (ETE) and unilateral multifocality progressively increased from 2008 to 2015 (2.1% to 24.3% and 4.2% to 22.8%, respectively). During the 88.6-month follow-up period, 67 (3.98%) recurrences and 2 (0.12%) deaths were observed. There were 269 (16.0%) multifocal DTC cases. There was no significant difference between the multifocal and unifocal groups in terms of the proportion of recurrences (5.2% vs. 3.7%) and distant metastasis (0.4% vs. 0.1%). Logistic regression analysis revealed age <42.5 years (OR=1.83), tumor diameter greater than 7.5 mm (OR=1.89), and N1a (OR=2.04) were potent risk factors for post-lobectomy recurrence. Conversely, male sex (OR=0.77; p=0.407), ETE (OR=1.16; p=0.698) and multifocality (OR=1.23; p=0.526) were not risk factors for recurrence after thyroid lobectomy. A positive node ratio (PNR) & GE;42.0%, N1a stage, a tumor diameter & GE;7.5mm and age <42.5 years were significant risk factors for recurrence (Log-rank p=0.001, p=0.001, p=0.004 and p=0.009, respectively). Contrariwise, multifocality and ETE were proven to not be risk factors for DTC recurrence after thyroid lobectomy (Log-rank p=0.099 and p=0.126, respectively). Conclusion: Unilateral multifocality was not a risk factor for DTC recurrence after thyroid lobectomy and could not be considered an indication for immediate completion or total thyroidectomy.
引用
收藏
页码:1802 / 1808
页数:7
相关论文
共 50 条
  • [1] Thyroid lobectomy is sufficient for differentiated thyroid cancer with upgraded risk after surgery
    Choi, Soon Min
    Kim, Dong Gyu
    Lee, Ji-Eun
    Ho, Joon
    Kim, Jin Kyong
    Lee, Cho Rok
    Kang, Sang-Wook
    Lee, Jandee
    Jeong, Jong Ju
    Chung, Woong Youn
    Nam, Kee-Hyun
    [J]. GLAND SURGERY, 2022, 11 (09) : 1451 - 1463
  • [2] Thyroid Lobectomy for Low to Intermediate Risk Differentiated Thyroid Cancer
    Hartl, Dana M.
    Guerlain, Joanne
    Breuskin, Ingrid
    Hadoux, Julien
    Baudin, Eric
    Al Ghuzlan, Abir
    Terroir-Cassou-Mounat, Marie
    Lamartina, Livia
    Leboulleux, Sophie
    [J]. CANCERS, 2020, 12 (11) : 1 - 18
  • [3] Association of Total Thyroidectomy or Thyroid Lobectomy With the Quality of Life in Patients With Differentiated Thyroid Cancer With Low to Intermediate Risk of Recurrence
    Chen, Wanna
    Li, Jie
    Peng, Sui
    Hong, Shubin
    Xu, Heyang
    Lin, Bo
    Liang, Xiaoli
    Liu, Yihao
    Liang, Jiadong
    Zhang, Zhaoxi
    Ye, Yingnan
    Liu, Fang
    Lin, Cuiyu
    Xiao, Haipeng
    Lv, Weiming
    [J]. JAMA SURGERY, 2022, 157 (03) : 200 - 209
  • [4] Risk of recurrence in differentiated thyroid cancer
    Miguel Dominguez, Jose
    Teresa Martinez, Maria
    Miguel Massardo, Jose
    Munoz, Sueli
    Droppelmann, Nicolas
    Gonzalez, Hernan E.
    Mosso, Lorena
    [J]. REVISTA MEDICA DE CHILE, 2018, 146 (03) : 282 - 289
  • [5] Multifocality of papillary thyroid carcinoma as a risk factor for disease recurrence
    Choi, Woo Ri
    Roh, Jong-Lyel
    Gong, Gyungyup
    Cho, Kyung-Ja
    Choi, Seung-Ho
    Nam, Soon Yuhl
    Kim, Sang Yoon
    [J]. ORAL ONCOLOGY, 2019, 94 : 106 - 110
  • [6] Frequency of Thyroid Hormone Replacement After Lobectomy for Differentiated Thyroid Cancer
    Schumm, Max A.
    Lechner, Melissa G.
    Shu, Michelle L.
    Ochoa, Joana E.
    Kim, Jiyoon
    Tseng, Chi-Hong
    Leung, Angela M.
    Yeh, Michael W.
    [J]. ENDOCRINE PRACTICE, 2021, 27 (07) : 691 - 697
  • [7] Bilaterality, not multifocality, is an independent risk factor for recurrence in low-risk papillary thyroid cancer
    Rodriguez Schaap, Pedro Manuel
    Lin, Jia Feng
    Metman, Madelon J. H.
    Dreijerink, Koen M. A.
    Links, Thera P.
    Bonjer, H. Jaap
    van Dijkum, Els J. M. Nieveen
    Dickhoff, Chris
    Kruijff, Schelto
    Engelsman, Anton F.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2023, 115 (09): : 1071 - 1076
  • [8] Use of Radioiodine after Thyroid Lobectomy in Patients with Differentiated Thyroid Cancer: Does It Change Outcomes?
    Kiernan, Colleen M.
    Parikh, Alexander A.
    Parks, Lee L.
    Solorzano, Carmen C.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2015, 220 (04) : 617 - 625
  • [9] SERUM THYROGLOBULIN ASSAYS AFTER TOTAL UNILATERAL THYROID LOBECTOMY FOR DIFFERENTIATED THYROID-CARCINOMA
    TOURNIAIRE, J
    BERNARD, MH
    AYZAC, L
    NICOLAS, MH
    BORNET, H
    [J]. PRESSE MEDICALE, 1990, 19 (28): : 1309 - 1312
  • [10] Thyroid lobectomy in patients with differentiated thyroid cancer: an analysis of the clinical outcomes in a nationwide multicenter study
    Diez, Juan J.
    Alcazar, Victoria
    Iglesias, Pedro
    Romero-Lluch, Ana
    Sastre, Julia
    Perez Corral, Begona
    Zafon, Carles
    Carlos Galofre, Juan
    Jose Pamplona, Maria
    [J]. GLAND SURGERY, 2021, 10 (02) : 678 - +